Page 59 - IMR ANNUAL REPORT 2021: INSTITUTE FOR MEDICAL RESEARCH
P. 59
46 IMR ANNUAL REPORT 2021
Generation of transgenic malaria using CRISPR-Cas9 system as seen in live-imaging, stained
nuclei with nucleus staining, and permanent stained with GIEMSA
Generation of transgenic malaria using CRISPR-Cas9 system as seen in live-imaging, stained
RESEARCH CENTRE (IDRC)
INFECTIOUS DISEASES
Generation of transgenic malaria using CRISPR-Cas9 system as seen in live-imaging, stained
nuclei with nucleus staining, and permanent stained with GIEMSA
Generation of transgenic malaria using CRISPR-Cas9 system as seen in live-imaging, stained
Generation of transgenic malaria using CRISPR-Cas9 system as seen in live-
nuclei with nucleus staining, and permanent stained with GIEMSA
Generation of transgenic malaria using CRISPR-Cas9 system as seen in live-imaging, stained
imaging, stained nuclei with nucleus staining, and permanent stained with
nuclei with nucleus staining, and permanent stained with GIEMSA
nuclei with nucleus staining, and permanent stained with GIEMSA
GIEMSA
Novel yeast species,
Candida vulturna,
isolated from an
aspiration pneumonia
patient
Novel yeast species, Candida vulturna, isolated from an aspiration pneumonia patient
Novel yeast species, Candida vulturna, isolated from an aspiration pneumonia patient
Novel yeast species, Candida vulturna, isolated from an aspiration pneumonia patient
Novel yeast species, Candida vulturna, isolated from an aspiration pneumonia patient
Novel yeast species, Candida vulturna, isolated from an aspiration pneumonia patient
Using
pharmacokinetic-
pharmacodynamic
modelling to establish
an optimum dose
concentration
response relationship
on bacteria
Using pharmacokinetic-pharmacodynamic modelling to establish an optimum dose concentration
response relationship on bacteria
Using pharmacokinetic-pharmacodynamic modelling to establish an optimum dose concentration
Using pharmacokinetic-pharmacodynamic modelling to establish an optimum dose concentration
response relationship on bacteria
Using pharmacokinetic-pharmacodynamic modelling to establish an optimum dose concentration
response relationship on bacteria
Using pharmacokinetic-pharmacodynamic modelling to establish an optimum dose concentration
response relationship on bacteria
response relationship on bacteria
60
60
60
60
60
